

# Jung-Hwan Yoon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6763602/publications.pdf>

Version: 2024-02-01

278  
papers

11,952  
citations

26630

56  
h-index

38395

95  
g-index

281  
all docs

281  
docs citations

281  
times ranked

15519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 503-508.	0.9	896
2	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2117-2127.	2.8	496
3	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	1.3	371
4	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. <i>Radiology</i> , 2011, 258, 627-634.	7.3	264
5	Nonalcoholic fatty liver disease is associated with coronary artery calcification. <i>Hepatology</i> , 2012, 56, 605-613.	7.3	259
6	Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. <i>Journal of Hepatology</i> , 2012, 57, 150-156.	3.7	234
7	Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. <i>Hepatology</i> , 2016, 64, 2185-2197.	7.3	213
8	Death receptor-mediated apoptosis and the liver. <i>Journal of Hepatology</i> , 2002, 37, 400-410.	3.7	173
9	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. <i>Gastroenterology</i> , 2002, 122, 985-993.	1.3	166
10	Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2010, 70, 3034-3041.	0.9	166
11	Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1160-1173.	7.3	165
12	Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. <i>Journal of Hepatology</i> , 2005, 42, 358-364.	3.7	164
13	Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2056-2064.	7.0	157
14	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	9.4	157
15	COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. <i>Hepatology</i> , 2002, 35, 552-559.	7.3	141
16	Bile acids activate EGF receptor via a TGF- $\beta$ -dependent mechanism in human cholangiocyte cell lines. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G31-G36.	3.4	134
17	Association of TNF- $\alpha$ promoter polymorphisms with the clearance of hepatitis B virus infection. <i>Human Molecular Genetics</i> , 2003, 12, 2541-2546.	2.9	132
18	Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 69-75.	2.2	130

#	ARTICLE	IF	CITATIONS
19	Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. <i>World Journal of Biological Chemistry</i> , 2015, 6, 148.	4.3	119
20	Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2004, 41, 808-814.	3.7	117
21	The Relation Between Non-Alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease in Koreans. <i>American Journal of Gastroenterology</i> , 2009, 104, 1953-1960.	0.4	117
22	Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 132-138.e4.	4.4	117
23	Molecular Epidemiology of Hepatitis B Virus (HBV) Genotypes and Serotypes in Patients with Chronic HBV Infection in Korea. <i>Intervirology</i> , 2007, 50, 52-57.	2.8	110
24	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial. <i>International Journal of Cancer</i> , 2015, 136, 1458-1467.	5.1	109
25	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. <i>Nature Communications</i> , 2017, 8, 839.	12.8	107
26	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	3.7	107
27	Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus Endemic Area: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 4459-4465.	1.6	106
28	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. <i>Human Molecular Genetics</i> , 2013, 22, 4233-4238.	2.9	105
29	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. <i>Annals of Surgery</i> , 2016, 263, 842-850.	4.2	105
30	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 347-354.	3.7	103
31	Bile Acids Stimulate cFLIP Phosphorylation Enhancing TRAIL-mediated Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 454-461.	3.4	102
32	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 649-652.	2.5	100
33	Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2554-2562.	4.1	100
34	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. <i>Radiology</i> , 2014, 271, 909-918.	7.3	97
35	Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 383.	8.9	96
36	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 5976-5985.	7.0	95

#	ARTICLE	IF	CITATIONS
37	Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. <i>Journal of Medical Virology</i> , 2005, 76, 194-202.	5.0	94
38	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	7.3	92
39	Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients. <i>Korean Journal of Radiology</i> , 2006, 7, 257.	3.4	85
40	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e2159.	1.0	85
41	RNA Interference Therapy With AR-C1520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84
42	Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. <i>Hepatology</i> , 2004, 39, 732-738.	7.3	83
43	Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tff 50 <i>Journal of Cancer</i> , 2013, 132, 2448-2458.	5.1	81
44	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 259-264.	2.9	78
45	Wnt signaling enhances the activation and survival of human hepatic stellate cells. <i>FEBS Letters</i> , 2007, 581, 2954-2958.	2.8	77
46	Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 1725-1734.	30.7	76
47	Association of transforming growth factor- $\beta$ 1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. <i>Experimental and Molecular Medicine</i> , 2003, 35, 196-202.	7.7	74
48	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 747-e218.	3.7	72
49	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. <i>Cancer Research</i> , 2002, 62, 6500-5.	0.9	72
50	The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. <i>Journal of Medical Virology</i> , 2008, 80, 1189-1194.	5.0	67
51	Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1226-1231.	2.8	66
52	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	4.2	62
53	Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. <i>Liver Transplantation</i> , 2009, 15, 496-503.	2.4	61
54	Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 775-781.	2.8	59

#	ARTICLE	IF	CITATIONS
55	Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 156-161.	2.1	58
56	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	8.1	58
57	SPP1 polymorphisms associated with HBV clearance and HCC occurrence. <i>International Journal of Epidemiology</i> , 2007, 36, 1001-1008.	1.9	57
58	Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area. <i>Digestion</i> , 2011, 84, 17-22.	2.3	57
59	Percutaneous Radiofrequency Ablation with Multiple Electrodes for Medium-Sized Hepatocellular Carcinomas. <i>Korean Journal of Radiology</i> , 2012, 13, 34.	3.4	57
60	<sc>CLIF</sc>â€<sc>SOFA</sc> scoring system accurately predicts shortâ€term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. <i>Liver International</i> , 2015, 35, 46-57.	3.9	55
61	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. <i>World Journal of Gastroenterology</i> , 2015, 21, 6287.	3.3	51
62	High titers of antiâ€HBs prevent rituximabâ€related viral reactivation in resolved hepatitis B patient with nonâ€Hodgkin's lymphoma. <i>Journal of Medical Virology</i> , 2016, 88, 1010-1017.	5.0	50
63	High Viremia, Prolonged Lamivudine Therapy and Recurrent Hepatocellular Carcinoma Predict Posttransplant Hepatitis B Recurrence. <i>American Journal of Transplantation</i> , 2010, 10, 1658-1668.	4.7	49
64	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 298, 9-15.	7.2	49
65	Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. <i>Liver International</i> , 2015, 35, 944-952.	3.9	49
66	Population Genotyping of Hepatitis C Virus by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Analysis of Short DNA Fragments. <i>Clinical Chemistry</i> , 2005, 51, 1123-1131.	3.2	48
67	Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. <i>Thrombosis Research</i> , 2018, 163, 71-76.	1.7	47
68	Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. <i>Journal of Medical Virology</i> , 2008, 80, 1337-1343.	5.0	45
69	Association of Metabolic Risk Factors With Risks of Cancer and Allâ€Cause Mortality in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 2266-2277.	7.3	45
70	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. <i>PLoS ONE</i> , 2014, 9, e105679.	2.5	43
71	Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 274-283.	0.5	42
72	Development of a Non-Transformed Human Liver Cell Line with Differentiated-Hepatocyte and Urea-Synthetic Functions: Applicable for Bioartificial Liver. <i>International Journal of Artificial Organs</i> , 1999, 22, 769-777.	1.4	41

#	ARTICLE	IF	CITATIONS
73	Heat Shock Protein 90 Inhibitor Induces Apoptosis and Attenuates Activation of Hepatic Stellate Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 276-282.	2.5	41
74	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 101-115.	2.3	39
75	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. <i>PLoS ONE</i> , 2016, 11, e0160822.	2.5	38
76	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. <i>Atherosclerosis</i> , 2018, 272, 137-144.	0.8	38
77	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine-Choline-Deficient Diet. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1461-1474.	2.3	37
78	Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 9449.	3.3	37
79	Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 495-501.	1.3	36
80	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0133935.	2.5	36
81	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 544-553.	12.0	36
82	Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2018, 64, 1230-1238.	3.2	36
83	HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 776-781.	2.1	35
84	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 912-920.	6.1	35
85	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. <i>Journal of Gastroenterology</i> , 2013, 48, 1401-1410.	5.1	35
86	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 855-868.	7.3	35
87	Modulation of cytokeratin expression during in vitro cultivation of human hepatic stellate cells: evidence of transdifferentiation from epithelial to mesenchymal phenotype. <i>Histochemistry and Cell Biology</i> , 2002, 118, 127-136.	1.7	34
88	Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. <i>Lung Cancer</i> , 2010, 70, 295-300.	2.0	33
89	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	2.5	33
90	Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. <i>Journal of Infection</i> , 2010, 61, 323-329.	3.3	32

#	ARTICLE	IF	CITATIONS
91	Caudate Lobe Hepatocellular Carcinoma Treated with Selective Chemoembolization. <i>Radiology</i> , 2010, 257, 278-287.	7.3	32
92	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 635-643.	2.5	32
93	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6710-6716.	3.2	32
94	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.5	32
95	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1292.	4.1	32
96	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	8.9	32
97	Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2130-2136.	2.3	31
98	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 813-819.	2.3	31
99	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , 2017, 27, 1448-1458.	4.5	31
100	Experimental Agents Which Inhibit Hepatocarcinogenesis. <i>Oncology</i> , 2008, 75, 17-21.	1.9	30
101	Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring. <i>PLoS ONE</i> , 2013, 8, e63468.	2.5	30
102	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 607-616.	5.6	30
103	Eupatilin attenuates bile acid-induced hepatocyte apoptosis. <i>Journal of Gastroenterology</i> , 2006, 41, 772-778.	5.1	29
104	Analysis of hepatitis B virus quasispecies distribution in a Korean chronic patient based on the full genome sequences. <i>Journal of Medical Virology</i> , 2007, 79, 212-219.	5.0	29
105	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 497-507.	2.3	28
106	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. <i>Radiology</i> , 2013, 267, 638-647.	7.3	28
107	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Clinical Cancer Research</i> , 2013, 19, 4218-4227.	7.0	28
108	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1730-1737.	3.2	28



#	ARTICLE	IF	CITATIONS
109	Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. <i>Cancer Letters</i> , 2008, 271, 314-322.	7.2	27
110	Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G126-G132.	3.4	27
111	Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. <i>Intervirology</i> , 2013, 56, 84-90.	2.8	27
112	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Journal of Proteome Research</i> , 2017, 16, 1239-1248.	3.7	27
113	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	7.0	27
114	IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 38-44.	2.1	26
115	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. <i>Hepatology</i> , 2022, 76, 492-501.	7.3	26
116	Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e573.	1.0	25
117	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1312-1323.	3.8	25
118	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	3.7	25
119	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977.	3.7	25
120	Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 465-477.	4.9	24
121	Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. <i>Liver International</i> , 2015, 35, 2530-2536.	3.9	24
122	17 $\beta$ -estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1247-1254.	2.1	24
123	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	4.5	24
124	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	2.6	24
125	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021, 3, 100361.	4.9	24
126	Recurrent hepatocellular carcinoma after spontaneous regression. <i>Journal of Gastroenterology</i> , 2000, 35, 552-556.	5.1	23



#	ARTICLE	IF	CITATIONS
127	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	2.3	23
128	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	7.7	23
129	Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 707-717.	2.0	23
130	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. <i>PLoS ONE</i> , 2012, 7, e41983.	2.5	23
131	Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. <i>Liver International</i> , 2004, 24, 687-695.	3.9	22
132	Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2011, 17, 106.	1.5	22
133	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , 2011, 11, 435.	2.6	22
134	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2568-2577.	2.3	22
135	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	3.7	22
136	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	2.9	22
137	Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor- $\beta$ -dependent hepatic stellate cell activation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 1091-1096.	2.1	21
138	Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 444-452.	2.0	21
139	Clinical features of acute renal failure associated with hepatitis A virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 611-7.	2.0	21
140	Excellent Outcome in 238 Consecutive Living Donor Liver Transplantations Using the Right Liver Graft in a Large Volume Single Center. <i>World Journal of Surgery</i> , 2013, 37, 1419-1429.	1.6	21
141	Association of <i>VARS</i> and <i>SFTA</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2015, 35, 1934-1940.	3.9	21
142	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. <i>Journal of Korean Medical Science</i> , 2018, 33, e283.	2.5	21
143	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986607.	3.2	21
144	Diagnosis, staging, and treatment of cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 105-112.	0.8	20

#	ARTICLE	IF	CITATIONS
145	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. <i>Endocrine-Related Cancer</i> , 2014, 21, 343-353.	3.1	20
146	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 444-449.	2.2	20
147	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 972-978.	3.2	20
148	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
149	Efficacy of thymosin $\alpha$ -1 plus peginterferon $\alpha$ -2a combination therapy compared with peginterferon $\alpha$ -2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1048-1055.	1.5	19
150	Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2012, 37, 439-446.	2.0	19
151	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. <i>Liver International</i> , 2013, 33, 884-893.	3.9	19
152	MicroRNA-196A polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2014, 86, 446-453.	5.0	19
153	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	6.4	19
154	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Liver Cancer</i> , 2021, 10, 72-81.	7.7	19
155	Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 21-26.	2.9	18
156	Putative association of transforming growth factor- $\beta$ polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 518-26.	2.0	18
157	STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 612-616.	5.6	18
158	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. <i>PLoS ONE</i> , 2014, 9, e100870.	2.5	18
159	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. <i>PLoS ONE</i> , 2017, 12, e0174271.	2.5	18
160	Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 389-395.	0.9	18
161	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 307.	2.6	18
162	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. <i>Korean Journal of Radiology</i> , 2021, 22, 1974.	3.4	18

#	ARTICLE	IF	CITATIONS
163	Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. <i>Oncology Reports</i> , 2011, 25, 1739-46.	2.6	17
164	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1638-1645.	2.8	17
165	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. <i>European Radiology</i> , 2019, 29, 3122-3131.	4.5	17
166	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. <i>BMC Cancer</i> , 2020, 20, 504.	2.6	17
167	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. <i>PLoS ONE</i> , 2014, 9, e113926.	2.5	17
168	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. <i>Gut and Liver</i> , 2020, 14, 755-764.	2.9	17
169	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. <i>Journal of Medical Virology</i> , 2012, 84, 424-430.	5.0	16
170	Relationship between polymorphisms near the <i>IL28B</i> gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 163-170.	2.0	16
171	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2037-2045.	2.5	16
172	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in <i>Gulo (gulo)</i> mice. <i>European Journal of Pharmacology</i> , 2015, 762, 247-255.	3.5	16
173	Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 28.	2.7	16
174	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 580.	1.7	16
175	Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. <i>Hepato-Gastroenterology</i> , 2006, 53, 266-70.	0.5	16
176	Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 771-779.	2.5	15
177	Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5511-5519.	3.2	15
178	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1859-1868.	2.8	15
179	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2015, 35, 1992-2000.	3.9	15
180	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 286-291.	8.9	15

#	ARTICLE	IF	CITATIONS
181	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	3.0	15
182	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. <i>Oncology Reports</i> , 2006, 15, 1117-23.	2.6	15
183	Characterization of Two Hepatitis B Virus Populations in a Single Korean Hepatocellular Carcinoma Patient with an HBeAg-Negative Serostatus: A Novel X-Gene-Deleted Strain with Inverted Duplication Sequences of Upstream Enhancer Site II. <i>Intervirology</i> , 2007, 50, 273-280.	2.8	14
184	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2015, 87, 575-582.	5.0	14
185	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2016, 11, e0161980.	2.5	14
186	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. <i>Digestion</i> , 2011, 84, 23-28.	2.3	13
187	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6325-6332.	3.2	13
188	Measurement of Glycosylated Alpha-Fetoprotein Improves Diagnostic Power over the Native Form in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110366.	2.5	13
189	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 696-705.	2.8	13
190	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. <i>Medicine (United States)</i> , 2016, 95, e4551.	1.0	13
191	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. <i>Cancer Biology and Therapy</i> , 2017, 18, 67-75.	3.4	13
192	Identification of novel <i>OCT4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2017, 37, 354-361.	3.9	13
193	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 66-73.	8.9	13
194	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, e18-e26.	2.2	13
195	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. <i>Genes and Immunity</i> , 2019, 20, 1-9.	4.1	13
196	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	2.8	13
197	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	4.4	13
198	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 133-144.	2.5	12

#	ARTICLE	IF	CITATIONS
199	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. <i>Korean Journal of Radiology</i> , 2017, 18, 799.	3.4	12
200	Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. <i>Clinical Infectious Diseases</i> , 2020, 73, e3308-e3316.	5.8	12
201	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.	8.9	12
202	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1565-1577.	3.7	12
203	Augmentation of urea-synthetic capacity by inhibition of nitric oxide synthesis in butyrate-induced differentiated human hepatocytes. <i>FEBS Letters</i> , 2000, 474, 175-178.	2.8	11
204	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 295, 229-235.	7.2	11
205	Serum HBsAg levels during peginterferon $\alpha$ 2a treatment with or without thymosin $\alpha$ 1 in HBeAg-positive chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2011, 83, 88-94.	5.0	11
206	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. <i>PLoS ONE</i> , 2017, 12, e0170394.	2.5	11
207	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBsAg-positive high viral load chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 552-560.	2.0	11
208	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	3.7	11
209	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. <i>PLoS ONE</i> , 2014, 9, e90862.	2.5	11
210	Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1108-1113.	2.1	10
211	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi</i> , The, 2011, 57, 19.	0.4	10
212	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817.	2.3	9
213	A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2829-2838.	3.7	9
214	Human Chorionic Plate-Derived Mesenchymal Stem Cells Restore Hepatic Lipid Metabolism in a Rat Model of Bile Duct Ligation. <i>Stem Cells International</i> , 2017, 2017, 1-9.	2.5	9
215	Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 142-146.	2.8	9
216	Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 472.	4.1	9

#	ARTICLE	IF	CITATIONS
217	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 6009.	3.7	9
218	Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. <i>Liver</i> , 2002, 22, 426-432.	0.1	8
219	Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. <i>Intervirology</i> , 2005, 48, 230-238.	2.8	8
220	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2017, 12, e0166188.	2.5	8
221	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 261-268.	1.7	8
222	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	3.7	8
223	Epidemiological and Clinical History of Viral Hepatitis in Korea. <i>Infection and Chemotherapy</i> , 2021, 53, 159.	2.3	8
224	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. <i>Korean Journal of Radiology</i> , 2021, 22, 179.	3.4	8
225	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0130392.	2.5	8
226	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. <i>PLoS ONE</i> , 2020, 15, e0239733.	2.5	8
227	Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. <i>Journal of Korean Medical Science</i> , 2020, 35, e117.	2.5	8
228	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. <i>Oncology Reports</i> , 0, , .	2.6	8
229	Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling. <i>Molecular Medicine Reports</i> , 2015, 12, 8247-8252.	2.4	7
230	Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 937-945.	2.0	7
231	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. <i>Scientific Reports</i> , 2018, 8, 13651.	3.3	7
232	Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. <i>Journal of Bioenergetics and Biomembranes</i> , 2019, 51, 121-129.	2.3	7
233	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 1170.	2.6	7
234	15d-Deoxy- $\gamma$ -12,14-prostaglandin J2 modulates collagen type I synthesis in human hepatic stellate cells by inducing oxidative stress. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 361-367.	2.2	6



#	ARTICLE	IF	CITATIONS
235	Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2009, 274, 259-265.	7.2	6
236	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1363-1370.	2.3	6
237	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. <i>Journal of Medical Virology</i> , 2018, 90, 1593-1603.	5.0	6
238	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Journal of Hepatology</i> , 2018, 68, S37-S38.	3.7	6
239	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , 2021, 56, 570-580.	5.1	6
240	A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4103-4103.	1.6	6
241	Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3394-3405.	1.6	6
242	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2017, 49, 1273-1279.	0.9	5
243	Mesalamine-induced B7 <sub>1</sub> expression on hepatic stellate cells attenuates autoimmune liver injury. <i>Hepatology Research</i> , 2011, 41, 79-86.	3.4	4
244	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 243-250.	2.2	4
245	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. <i>Molecular Medicine Reports</i> , 2015, 11, 263-268.	2.4	4
246	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	1.5	4
247	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. <i>Journal of Bioenergetics and Biomembranes</i> , 2016, 48, 581-590.	2.3	4
248	Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. <i>Scientific Reports</i> , 2020, 10, 21313.	3.3	4
249	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 1001.	2.6	4
250	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. <i>Cancer Gene Therapy</i> , 2021, , .	4.6	4
251	CT Findings of Completely Regressed Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis after Transcatheter Arterial Chemoembolization. <i>Korean Journal of Radiology</i> , 2010, 11, 69.	3.4	3
252	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	2.3	3



#	ARTICLE	IF	CITATIONS
253	Augmentation of Butyrate-induced Differentiation of Human Hepatocyte by Cyclin E Over-expression. <i>International Journal of Artificial Organs</i> , 2005, 28, 44-50.	1.4	2
254	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 389.	1.5	2
255	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2020, 14, 225-231.	2.9	2
256	Molecular targeted therapy with transarterial chemoembolization. <i>Gastrointestinal Intervention</i> , 2013, 2, 78-81.	0.1	1
257	A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 655-661.	2.2	1
258	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	1.5	1
259	Drug response prediction model using a hierarchical structural component modeling method. <i>BMC Bioinformatics</i> , 2018, 19, 288.	2.6	1
260	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 587-598.	3.7	1
261	Lysophosphatidylcholine. , 2011, , 2127-2128.		1
262	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316.	1.6	1
263	Pathologically Confirmed Spontaneous Partial Regression of Hepatocellular Carcinoma. <i>Korean Journal of Medicine</i> , 2014, 86, 198.	0.3	1
264	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	2.9	1
265	Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?. <i>Gut and Liver</i> , 2016, 10, 497-498.	2.9	1
266	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. <i>Oncotarget</i> , 2017, 8, 47555-47564.	1.8	1
267	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Journal of Liver Cancer</i> , 2019, 19, 128-135.	1.1	1
268	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. <i>Gut and Liver</i> , 2020, 14, 377-386.	2.9	1
269	Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. <i>Journal of Medical Virology</i> , 2015, 87, 999-1007.	5.0	0
270	Reply. <i>Gastroenterology</i> , 2015, 149, 1640-1641.	1.3	0

#	ARTICLE	IF	CITATIONS
271	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3767-3774.	4.3	0
272	Analysis of significant protein abundance from multiple reaction-monitoring data. <i>BMC Systems Biology</i> , 2018, 12, 123.	3.0	0
273	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 370-377.	2.2	0
274	Development and validation of a scoring system using insulin-like growth factor to assess hepatic reserve in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 231-231.	1.6	0
275	Lysophosphatidylcholine. , 2014, , 1-3.		0
276	Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. , 2017, , 69-84.		0
277	Lysophosphatidylcholine. , 2017, , 2605-2607.		0
278	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq0 0 0 rgBT /25erlock 10 Tf 50 45		